Financing led by Yonjin Capital as well as current investors will allow the company to move its leading program to the clinic and strengthen its internal discovery pipeline
Read More
NEWS
EVENTS
Publications
NEWS
-
Metabomed completes a $12.5 million raise in order to advance its lead program into clinical studies
-
Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing
Existing Investors MS Ventures, Boehringer Ingelheim Venture Fund, Pontifax LLC and the Technion Research and Development Foundation are joined by Pfizer Inc. and Arkin Holdings Simone Botti, Head of MS Ventures Israel BioIncubator Fund, will join the company as full time CEO.
Read More -
Metabomed joins Merck Serono Israel Bioincubator
Metabomed will be financed by a syndicate led by MS Ventures together with Boehringer Ingelheim Venture Fund, Pontifax LLC and the Technion Research and Development Foundation Metabomed brings together three world-leading researchers to focus on drug discovery in the field of novel targets in cancer metabolism.
Read More
In The Press
-
Targeted cancer therapy co Metabomed raises $12.5m
globes, 19 Dec, 2019 | READ MORE -
Cancer Metabolism Company Metabomed Raises $12.5 Million
ctech, 19 Dec, 2019 | READ MORE -
Metabomed: A New Venture in Israel’s Start-Up Ecosystem that Tackles Cancer’s Altered Metabolism – A Chat with Simone Botti, Former Head of Merck Ventures’ Israel BioIncubator and CEO of Metabomed
wuxiapptec, 12 Sep, 2016 | READ MORE -
Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing
fierce biotech, 7 Apr, 2016 | READ MORE -
Cancer metabolism co Metabomed raises $18m
globes, 4 Apr, 2016 | READ MORE
Publications
-
Discovery of potent selective oral ACSS2 inhibitors for the treatment of acetate avid tumors
Keystone conference: Tumor Metabolism 2020 | READ MORE -
Differential viability screen against tumor cells displaying broken TCA cycle phenotype identifies novel class of Type I GluT inhibitors
Keystone conference: Tumor Metabolism 2019 | READ MORE -
Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase
Nature | READ MORE -
Predicting selective drug targets in cancer through metabolic networks
Mol Syst Biol | READ MORE -
Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality
CELL | READ MORE -
Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress
CANCER CELL | READ MORE -
Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis
Nature Cell Biology | READ MORE